Business
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
OSAKA, Japan & CAMBRIDGE, Mass., February 19, 2026--Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can offer the possibility of clinical remission for patients ages 2 and older with moderately to severely active ulcerative colitis (UC), a chronic inflammatory disease of the gastrointestinal tract and one of the two most common types of inflammatory bowel disease.1,2 The results, presented at the 21st
About this update from Takeda Pharmaceutical Co. Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/c1176f52e346cbaf3ddd4df18d2a4c4f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8P9rE3joQ_pyeT8KIOStuw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c1176f52e346cbaf3ddd4df18d2a4c4f","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/P2pYh0Y9onSArEG7msZhMA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/c1176f52e346cbaf3ddd4df18d2a4c4f","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor (TNF) antagonists, found nearly half (47.3%) of randomized patients achieved primary endpoint of clinical remission at 54 weeks","length":328,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Vedolizumab’s safety profile was generally consistent with its known safety profile in adults","length":93,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Results were presented at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO)","length":99,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":520,"olType":false},{"type":"text","content":"OSAKA, Japan & CAMBRIDGE, Mass., February 19, 2026--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can offer the possibility of clinical remission for patients ages 2 and older with moderately to severely active ulcerative colitis (UC), a chronic inflammatory disease of the gastrointestinal tract and one of the two most common types of inflammatory bowel disease.1,2 The results, presented at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO), show vedolizumab’s promising efficacy and safety profile in a patient population where therapy options remain limited. With KEPLER, Takeda is continuing to generate deeper scientific insights and...